Novavax vaccine: “Efficacy over 90% even against covid variants”

The anti-Covid vaccine from the American Novavax has shown an overall effectiveness of 90.4% in a phase 3 study that involved almost 30 thousand participants in 119 centers between the US and Mexico. The effectiveness was 100% in preventing moderate and severe forms of the disease, the company reports. The product, Novavax points out, also works against Sars-CoV-2 variants. In particular, it is 93% effective against the so-called variants of concern (Voc) and against the variants of interest (Voi) prevalently circulating, and 100% against variants not considered Voc / Voi. is 91%, the group adds. All hospitalizations / deaths occurred in the placebo group. Novavax’s is a protein-based vaccine – as described by the European Medicines Agency EMA, which has already started the cyclic review on the product – which contains tiny particles obtained from a laboratory-produced version of the Spike protein found on the surface of the pandemic coronavirus. It also uses an adjuvant, a substance that helps to strengthen immune responses stimulated by the injection-shield. The results of the ‘Prevent-19’ study “reinforce” the evidence “that NVX-CoV2373 is extremely effective and offers complete protection against the ‘Covid-19 infection, both moderate and severe “, says Stanley C. Erck, president and CEO of Novavax. The trial” confirms that NVX-CoV2373 offers a reassuring safety and tolerability profile – says Gregory M. Glenn, president of Research & Development, Novavax – These data show high levels of efficacy and reaffirm the vaccine’s ability to prevent Covid-19 at a stage in which the virus is undergoing genetic evolution. Our vaccine will make a fundamental contribution to the solution of the emergency Covid “, Glenn is convinced, thanking” the participants in the study, the operators who made it possible as well as our supporters, including the US government “.